175676-89-8

Upstream product

• 405-50-5 p-Fluorophenylacetic acid 
• 87483-29-2 2-(4-fluorophenyl)-1-(4-(methylthio)phenyl)ethanone 
• 100-68-5 methyl-phenyl-thioether 
• 165252-27-7 2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]-4,4,4-trifluoro-1,3-butanedione 

Downstream Products

• 175676-99-0 4-(4-fluorophenyl)-3-[4-(methylthio)phenyl]-1-propargyl-5-(trifluoromethyl)pyrazole 
• 175676-90-1 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole 
• 175676-93-4 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-3-(trifluoromethyl)pyrazole 
• 175676-91-2 1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole 

Relevant academic research and scientific papers

3,4-substituted pyrazoles for the treatment of inflammation

PCT No. PCT/US95/08788 Sec. 371 Date Jun. 9, 1997 Sec. 102(e) Date Jun. 9, 1997 PCT Filed Jul. 20, 1995 PCT Pub. No. WO96/03385 PCT Pub. Date Feb. 8, 1996A class of pyrazolyl compounds is described for use in treating inflammation and inflammation related

3,4-diarylpyrazoles: Potent and selective inhibitors of cyclooxygenase-2

A series of 3,4-diarylpyrazoles was synthesized and evaluated for their ability to selectively inhibit cyclooxygenase-2 (COX-2). A number of potent and selective inhibitors were identified and found to have oral anti-inflammatory activity in a rat carrageenan-induced foot pad edema assay.

3,4-substituted pyrazoles for the treatment of inflammation

A class of pyrazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: STR1 wherein R1 is selected from hydrido, alkyl, alkenyl, aralkyl, alky